Overview

SPP100 (Aliskiren) Regimen in Hypertensive Patients With Renal Dysfunction

Status:
Completed
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
Assessing the safety, efficacy and pharmacokinetics of SPP100 (Aliskiren) regimen in hypertensive patients with renal dysfunction
Phase:
Phase 3
Details
Lead Sponsor:
Novartis